Home › Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
 

Keywords :   


Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment

2015-11-20 04:25:37| drugdiscoveryonline Home Page

Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher A. Viehbacher, recently announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.

Tags: company point development capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 18
03.07Hurricane Beryl Wind Speed Probabilities Number 18
03.07Hurricane Beryl Public Advisory Number 18
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 18
03.07Hurricane Beryl Graphics
03.07Atlantic Tropical Weather Outlook
More »